The strong operational beat and margin expansion signal a turnaround in Bruker's core business, supported by robust bookings. The lowered revenue guidance is currency/tax-driven and not a demand issue. Traders should watch for continued margin expansion and organic growth in H2 2026, with the maintained EPS guidance implying stronger second-half performance.
Price Chart
Executive Summary
Bruker reported Q2 2026 revenue of $838.5M (+5.2% YoY, +2.8% organic), beating consensus of $853.6M on the top line. Non-GAAP EPS of $0.49 was well above the $0.38 consensus estimate, driven by strong margin expansion (non-GAAP operating margin 14.1% vs 9.0% a year ago) and 10% organic bookings growth in the Scientific Instruments segment. The company slightly lowered its FY2026 revenue guidance range to $3.54-$3.57B (from $3.57-$3.60B) due to currency and tax, but maintained its non-GAAP EPS guidance of $2.10-$2.15. A $134.9M non-cash goodwill impairment charge drove a GAAP loss of $(0.41) per share, but the underlying operational beat and margin story are the key takeaways for the common stock.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $838.5M, +5.2% YoY, +2.8% organically
- Non-GAAP EPS of $0.49 vs consensus $0.38, a 28.9% beat
- Non-GAAP operating margin expanded to 14.1% from 9.0% YoY
- BSI segment bookings up 10% organically YoY, book-to-bill >1.0x
- FY2026 revenue guidance lowered to $3.54-$3.57B (from $3.57-$3.60B) on currency/tax; non-GAAP EPS guidance maintained at $2.10-$2.15
- GAAP diluted loss per share of $(0.41) due to $134.9M goodwill impairment
Financial Impact
Non-GAAP EPS beat consensus by $0.11 (28.9%); revenue beat by $14.9M (1.8%)
Risk Factors
- US academic demand remains soft, which could pressure future organic growth
- Currency headwinds and tariff uncertainties continue to impact reported revenue
- The $134.9M goodwill impairment raises questions about prior acquisition discipline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-331511 |
| Document: brkr-20260804.htm | 0001193125-26-331511 |
| Document: 0001193125-26-331511-index-headers.html | 0001193125-26-331511 |
| Document: 0001193125-26-331511-index.html | 0001193125-26-331511 |
| Document: 0001193125-26-331511.txt | 0001193125-26-331511 |
| 8-K Data (Synthetic) | 0001193125-26-331511 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 6w ago | Insider Cluster | $56.60 $60.67 | ▲ +7.19% | ▲ +8.50% | $63.42 (+12.04%) |
Aug 14, 2026 6w ago | 8-K | $57.67 $55.75 | ▼ −3.33% | ▼ −1.35% | $63.42 (+9.96%) |
Aug 4, 2026 8w ago | 8-K | $50.30 $56.03 | ▲ +11.39% | ▲ +12.63% | $63.42 (+26.07%) |
Jun 11, 2026 16w ago | Institutional Cluster | $55.18 $60.58 | ▲ +9.79% | ▲ +7.90% | $63.42 (+14.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access